Navigation Links
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Date:7/1/2009

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a therapeutic monoclonal antibody. SEP(TM) is an integrated platform of proprietary systems for protein production, processing and purification.

"Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, President and Chief Executive Officer of Synageva BioPharma Corporation. "Their commitment to utilizing Synageva's platform is a testament to the strength of our science and product development capabilities and we are excited about the potential for this collaboration."

"We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I," stated Philip M. Sass, PhD, Executive Vice President and Chief Operating Officer, Morphotek, Inc. "We are always exploring new ways that may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc mission."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek develops optimized antibodies, including antibodies optimized for affinity and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The company has assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, inflammatory and infectious disease. The antibodies within the company's pipeline are targeted against a
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., , TSX VENTURE: HTL , TORONTO, Nov... (TSX-V: HTL), formerly Calotto Capital Inc., a le...uments for the stem cell research and fertility cl...cial results for the third quarter ended September...enue was $1.46 million compared with $1.43 million...
(Date:11/24/2009)..., , SAN DIEGO, Nov. 24, 2009 /PRNewsw...daq: ARNA ) announced today that the company is...nual Health Care Conference on December 1, 2009 at...at the New York Palace Hotel in New York City. Jac...cer, is scheduled to provide an overview of the co...
(Date:11/24/2009)...,, BOZEN,Italy,November24/PRNewswire/--Healt...njointventurewithagroupofselected,investors.Thisre...e,nameHealthRoboticsCanada,Inc.andwillmarket,insta...ncept,whichincludesthe,revolutionaryproductofferin...oboticsCanadaInc.willalsoprovideassistanceonan"asn...
(Date:11/24/2009)..., Chemical Abstracts Serv...on, reports that China,s patent office is now the ...cations in chemistry. China trailed Japan,s patent...ion (WIPO), and the United States Patent and Trade...ssed the USPTO in 2005, WIPO in 2006, and exceeded...
Breaking Biology Technology:Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
...fety of patients treated with,Myobloc(R) (Botulinu...n of,primary importance for Solstice Neurosciences...ning of physicians in a number of ways regarding,t...rescribing information., We maintain a rigorous a...y adverse events to regulatory authorities in comp...
... Schering-Plough,Corporation (NYSE: SGP ) today ... Schering-Plough Research Institute (SPRI), the re...acqueline Elbonne, Ph.D., has been named vice pres...mediately. In this position, Elbonne,will build an...g all SPRI,activities governed by current Good Man...
...sor to Company, FRAZER, Pa., Feb. 8 Cephalon, In...ive Vice President, General Counsel &,Secretary, J...with the,company, effective March 31. Mr. Osborn h...n significant legal and policy matters., "John ha...e team and is,an exceptionally talented lawyer. On...
Other Biology Technology:Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication 2Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute 2Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute 3Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3
(Date:11/23/2009)...trong evidence that the "synergistic" effect of ea...pollution and indoor endotoxin causes more harm to...lone. , Environmental health scientists at the... have shown that children exposed to both high lev...xin during early life are six times more likely to...
(Date:11/23/2009)..., 2009 Applied mathematicians dissected the morph... characteristic long leaf with a saddle-like arc m...es. The simple cause of the lily,s fan-like shapee...fferential growthwas revealed by using an equally ...yi Liang, a postdoctoral student at Harvard,s Scho...
(Date:11/23/2009)...servation Society says that western lowland gorill...opart of the "mother lode" of more than 125,000 go...ly threatened by growing humans activity in the re...wamp forests adjacent to the southwest border of L...rmed that high densities of the great apes still e...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2The cause behind the characteristic shape of a long leaf revealed 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Council for American Medical Innovation Honors Health Champion Senator Edward M Kennedy 55457 1Council for American Medical Innovation Honors Health Champion Senator Edward M Kennedy 55457 2Council for American Medical Innovation Honors Health Champion Senator Edward M Kennedy 55457 3Wheat Consumption May Contribute to Diabetes 55456 1Gene assay to help to predict lung cancer treatment resistance 55452 1
...mpany Metabolic Pharmaceuticals Limited recently a...of the toxin. The company will begin clinical tria... of the toxin in normal males, and later its effec...ed with diabetes. , From the University of Melbour...ogy and the recently launched Bio21 Institute, Ass...
...t stem cells are controversial. Many people know t...pe found in the body, from a red blood cell to a m...s why stem cells continue to divide and renew them... dividing. , Now scientists at Northwestern Univer... the first clues as to why stem cells ignore stop ...
... questions in modern oceanography is how animals i...s at the Monterey Bay Aquarium Research Institute ...er this question, at least for animals that live o...ornia. After analyzing hundreds of hours of deep-s...hat "sinkers"-the cast-off mucus nets of small mid...
Other Biology News:Molecular miners find pain relief drugs from the sea 2Molecular miners find pain relief drugs from the sea 3Discovery suggests why stem cells run through stop signs 2'Sinkers' provide missing piece in deep-sea puzzle 2'Sinkers' provide missing piece in deep-sea puzzle 3'Sinkers' provide missing piece in deep-sea puzzle 4
CD25 MicroBeads, non-human primate from Miltenyi Biotec
...tors are designed for enhanced translation of clon...s, e.g. rabbit reticulocyte lysate. The maps for p...a(+) with the following exceptions: pCITE-2b(+) is... and Xcm I sites. Subtract 7 bp from all sites bey...
Mouse Anti-Human Non-SMC condensin II complex, subunit D3 (NCAPD3) Monoclonal Antibody, Unconjugated from Lifespan Biosciences
Flp-In T-REx Core Kit from Invitrogen
Biology Products: